QR kód

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics

Background: In the context of hormone receptor positive, HER2 negative Metastatic breast cancer (MBC), CDK 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the standard first-line treatment, improving Progression-Free Survival (PFS) and Overall Survival (OS). Despite these benefits...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lorenzo Foffano, Alessandra Franzoni, Elisabetta Molteni, Fabiola Giudici, Arianna Dri, Debora Basile, Linda Cucciniello, Silvia Buriolla, Claudia Noto, Stefania Russo, Elena Nascimbeni, Silvia Bolzonello, Brenno Pastò, Serena Della Rossa, Lorenzo Allegri, Marta Bonotto, Alessandro Marco Minisini, Barbara Belletti, Giuseppe Damante, Lorenzo Gerratana, Fabio Puglisi
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-09-01
Edice:Translational Oncology
Témata:
On-line přístup:http://www.sciencedirect.com/science/article/pii/S1936523325001871
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!